• If you are wondering whether Bausch + Lomb shares offer good value at today's price, it helps to start by looking at what the market has been willing to pay for them recently and how that lines up with the fundamentals we can see.
• The stock closed at US$16.85 most recently, with a 2.0% decline over the last week, a 1.8% decline over the last month, a 1.6% gain year to date, and a 4.5% decline over the past year. Together, these figures give you a mixed picture of how sentiment has shifted over different timeframes.
• Recent news around Bausch + Lomb has focused on its position in eye health and broader healthcare trends, which continues to keep the company on the radar for investors tracking the sector. These headlines help frame how the market may be reassessing both the risks and potential of the business over the past year.
• Against this backdrop, Bausch + Lomb currently holds a valuation score of 5/6, reflecting how it screens on several standard checks for being undervalued. Next, we look at what different valuation methods suggest about the stock, before finishing with an approach that can help you put all of these numbers into a clearer real world context.

Approach 1: Bausch + Lomb Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow model takes forecasts of a company’s future cash flows and discounts them back to today using a required rate of return, aiming to estimate what the whole business might be worth in today’s dollars.

For Bausch + Lomb, the model used is a 2 Stage Free Cash Flow to Equity approach based on cash flow projections. The latest twelve month free cash flow figure is a loss of $121.26 million, so the valuation leans heavily on expectations that future free cash flows turn positive. Simply Wall St has a forecast for free cash flow of $302.30 million in 2026, with further projections extended out to 2035, where projected annual free cash flow reaches $2.54 billion. These longer term numbers are extrapolated beyond the initial analyst estimates.

On this basis, the model arrives at an estimated intrinsic value of about $80.16 per share. Compared with the recent share price of $16.85, the DCF suggests the stock is around 79.0% undervalued.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests Bausch + Lomb is undervalued by 79.0%. Track this in your watchlist or portfolio, or discover 869 more undervalued stocks based on cash flows.

Approach 2: Bausch + Lomb Price vs Sales

For companies where earnings can be uneven or negative, the P/S ratio is often more useful because it compares the share price to revenue, which tends to be more stable than earnings. It gives you a cleaner view of how much investors are paying for each dollar of sales.

What counts as a “normal” P/S ratio depends heavily on how quickly revenue is expected to grow and how risky the business is. Higher growth or lower risk usually supports a higher multiple, while slower growth or higher risk points to a lower one.

Bausch + Lomb currently trades on a P/S of 1.20x. That sits below the Medical Equipment industry average of 3.20x and below the peer group average of 2.51x. Simply Wall St’s Fair Ratio for Bausch + Lomb is 2.42x, which is its proprietary estimate of what the P/S should be after factoring in growth prospects, profit margins, industry, market cap and risk. This Fair Ratio can be more tailored than a simple comparison with peers or the broader industry, which may have very different profiles. With the Fair Ratio above the current 1.20x, the P/S lens points to the shares trading at a discount.

Result: UNDERVALUED

P/S ratios tell one story, but what if the real opportunity lies elsewhere? Discover 1418 companies where insiders are betting big on explosive growth.

Upgrade Your Decision Making: Choose your Bausch + Lomb Narrative

Earlier we mentioned that there is an even better way to understand valuation, so let us introduce you to Narratives. A Narrative is simply your story about a company, backed up by your own assumptions for fair value, future revenue, earnings and profit margins, instead of relying only on preset models. On Simply Wall St, within the Community page used by millions of investors, you can pick a Narrative that links Bausch + Lomb’s business story to a financial forecast, which then flows through to an estimated fair value per share. That fair value can then be compared directly with today’s share price to help you decide whether you see Bausch + Lomb as closer to a buy, a hold, or a sell, based on your view and risk comfort. Narratives update automatically when new information such as earnings reports or news arrives, so your story and numbers stay aligned. For example, one investor might set a higher fair value for Bausch + Lomb based on stronger revenue and margin expectations, while another might choose a much lower fair value if they assume slower growth or more cautious profitability.

Do you think there's more to the story for Bausch + Lomb? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.